(AVNS) Avanos Medical - Ratings and Ratios

Avanos Medical, Inc. is a medical technology company that provides a range of medical device solutions across the globe, with a significant presence in North America, Europe, and other regions. The companys product portfolio is diversified across digestive health, non-opioid pain solutions, and interventional pain solutions, catering to various healthcare needs. Avanos Medicals digestive health products include enteral feeding tubes, patient feeding solutions, and neonatal and pediatric feeding solutions, while its pain management offerings comprise surgical pain pumps, cold and compression therapy systems, and minimally invasive pain-relieving therapies.

The companys business model involves direct marketing to hospitals, healthcare providers, and facilities, as well as distribution through third-party wholesale distributors. With its headquarters in Alpharetta, Georgia, Avanos Medical has established itself as a player in the healthcare supplies industry. The companys history dates back to 2014 when it was incorporated as Halyard Health, Inc., before rebranding to Avanos Medical, Inc. in 2018.

Analyzing the technical data, Avanos Medicals stock price is currently at $12.58, with a 20-day Simple Moving Average (SMA) of $12.44, indicating a potential bullish trend. However, the 50-day SMA and 200-day SMA are at $13.69 and $18.54, respectively, suggesting a longer-term downtrend. The Average True Range (ATR) is 0.55, representing a 4.37% volatility. Considering the fundamental data, the companys market capitalization stands at $565.38 million, with a negative Return on Equity (RoE) of -34.79%. Given the absence of a reported P/E ratio, it is likely that the company is currently unprofitable.

Based on the technical and fundamental analysis, a forecast for Avanos Medicals stock price could be constructed. The current price is near its 52-week low, and the short-term SMA indicates a potential stabilization. However, the longer-term SMAs and the negative RoE raise concerns about the companys profitability and growth prospects. Assuming the company addresses its profitability issues, a potential price target could be around $15-$18, representing a 20-40% increase from the current price. Nevertheless, this forecast is contingent upon significant improvements in the companys financial performance and a reversal of the current downtrend.